Raportul
Știri verificate despre finanțări, sedii centrale și leadership de la cele mai inovatoare companii din lume
22 rapoarte și mai multe
OMass Therapeutics Raises $310M Series C for Small-Molecule Therapeutics
OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance its small molecule pipeline in endocrinology and immunology.
Khartis Therapeutics Raises $50M Series B for Oral Immunology Medicines
Khartis Therapeutics raised a $50 million Series B led by Forge Life Science Partners to advance its oral IGF-1R inhibitor for thyroid eye disease.
Boulevard Bio Launches With Approximately $65M From Deerfield for Precision Immunology
Boulevard Bio announced its emergence from stealth with approximately $65 million in aggregate financing from Deerfield and affiliates, provided in equity capital and convertible notes.
Infinimmune Raises $75M Series A for Human-Derived Antibody Drugs
Infinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance human-derived antibody programs in atopic dermatitis and inflammatory disease.
Dualitas Therapeutics Appoints Karim Dabbagh Chief Executive Officer
Dualitas Therapeutics appointed Karim Dabbagh, formerly President and CEO of Silver Creek Pharmaceuticals, as Chief Executive Officer, with former interim CEO Rich Murray remaining on the Board of Directors.
Eli Lilly and Company Headquarters - Office Location & Address
Discover Eli Lilly and Company's headquarters at 893 S Delaware St, Indianapolis, IN 46225. Pharmaceutical company discovering, developing, and marketing medicines for diabetes, oncology, immunology, and neuroscience. Leading provider of insulin and diabetes care with strong pipeline in oncology and immunology.. Learn about the office facilities and work environment.
Electra Therapeutics Raises $183 Million in Series C - October 22, 2024
Electra Therapeutics announced $183 Million in Series C funding at a Undisclosed valuation. Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and...
Bambusa Therapeutics raises $90M Series A at $400M valuation
Bambusa Therapeutics raises $90M in Series A at $400M valuation. Bispecific antibodies for immunology...
Evommune raises $50M Series B at $300M valuation
Evommune raises $50M in Series B at $300M valuation. Oral immunology treatments...
Afișare 9 rapoarte • Pagina 1 • Categorie: all
Rămâneți înaintea pieței
Primiți perspective săptămânale în inbox. Fără spam, doar inteligență.



